From lab to bedside: emerging clinical applications of thymosin α1

@article{Goldstein2009FromLT,
  title={From lab to bedside: emerging clinical applications of thymosin $\alpha$1},
  author={Allan L Goldstein and Adam L Goldstein},
  journal={Expert Opinion on Biological Therapy},
  year={2009},
  volume={9},
  pages={593 - 608}
}
Background: Thymosin α1 (Tα1), a synthetic version of a thymic-derived biological response modifier was the first of the thymosins in clinical use. Tα1 is approved in over 35 countries for the treatment of hepatitis B and C, and as an immune stimulant and adjuvant. Tα1 is also in late-stage clinical testing in the United States and Europe for hepatitis C and stage IV melanoma. Objective/methods: Novel applications and other recently completed trials point to much broader clinical applications… Expand
Evaluation of thymosin α 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis
TLDR
These initial pilot studies support the hypothesis that immune-suppressive indications, including sepsis and melanoma, may be treated with Ta1 alone or by Ta1 in combination with other immunotherapies. Expand
Serum thymosin alpha 1 levels in normal and pathological conditions
TLDR
Evidence is growing that diseases characterized by deregulation of immune and/or inflammatory responses are associated with serum levels of Ta1 significantly lower than those of healthy individuals: to date, B hepatitis, psoriatic arthritis, multiple sclerosis and sepsis. Expand
The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials
TLDR
Tα1 may be beneficial to sepsis patients in reducing mortality and modulating inflammation reactions, however, the quality of evidence supporting the effectiveness is low considering the small sample sizes and inadequate adherence to standardized reporting guidelines for RCTs among the included studies. Expand
Myelo-and immunotropic properties of thymic hormones – clinical use in hematology and oncology
The concept of using the thymominetic drugs in haematology and oncology is based on growing body of evidence of the role of thymus and its hormones in control of immune reactivity. Thymic hormonesExpand
Combination Therapy with Thymosin Alpha1 and Dexamethasone Helps Mice Survive Sepsis
TLDR
Immunomodulatory therapy that combines Tα1 and DXM in a timely manner and was based on changes in DCs enhanced the resistance of endotoxemic mice to bacterial translocation and secondary infections, improving the outcome of the infection. Expand
Cellular proteostasis: a new twist in the action of thymosin α1
TLDR
By providing a multipronged attack against CF, Tα1 favorably opposed CF symptomatology in preclinical relevant disease settings, thus suggesting its possible exploitation for ‘real-life’ clinical efficacy in CF. Expand
Thymosin alpha 1 and HIV-1: recent advances and future perspectives.
TLDR
The present knowledge on the in vitro and in vivo studies concerning the use of thymosin alpha 1 in HIV-1 infection and recent findings and future perspectives of therapeutic intervention are reported. Expand
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
TLDR
Current understanding of the pathogenic mechanisms involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the progression of coronav virus disease 2019 (COVID-19) is described, focusing on the immunological hyper-response and the induction of widespread endothelial damage, complement-associated blood clotting and systemic microangiopathy, as well as the effects of these processes on the kidney. Expand
Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases
TLDR
A cohort of healthy individuals in comparison with patients affected by chronic inflammatory autoimmune diseases was studied, finding that serum Tα1 levels were significantly lower than in HC and there was no treatment‐related difference in PsA group. Expand
Deciphering cellular biological processes to clinical application: a new perspective for Tα1 treatment targeting multiple diseases
TLDR
The network enrichment analysis demonstrated that T α1 regulates cellular metabolic processes and oxidative stress response, suggesting new translational implication of Tα1 treatment in pathological conditions unexpected until now. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 150 REFERENCES
Immunoregulation of Thymosin α 1 Treatment of Cytomegalovirus Infection Accompanied With Acute Respiratory Distress Syndrome After Renal Transplantation
TLDR
It is suggested that thymosin α1 significantly promoted CD4+ and CD8+ lymphocytes, repairing cellular immunity and successfully reinforcing resistance to cytomegalovirus disease. Expand
Thymosin Alpha 1
TLDR
Pivotal trials in advanced non‐small cell lung cancer and melanoma with Tα1 and IFN‐α low doses after cis‐platinum or dacarbazine produced the first evidence of the high potentiality of this approach in the treatment of human cancer. Expand
Thymosin Alpha 1 as an Adjunct to Influenza Vaccination in the Elderly
TLDR
The findings to date warrant additional efforts to further examine the role of Tα1 in augmenting specific vaccine responses both in the elderly or in younger subjects in situations in which there are suboptimal quantities of immunizing antigen available. Expand
Combination therapy with BRMs in cancer and infectious diseases
TLDR
The studies have demonstrated that treatment with Thymosin alpha-1 and low doses of IFN or IL-2 exert powerful biological effects both in vitro and in vivo and are highly effective in restoring cytotoxic activities in immunosuppression induced by tumors and/or cytostatic drugs. Expand
A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer.
TLDR
Thymosin treatment was associated with significant improvements in relapse-free and overall survival, which was most pronounced for patients with nonbulky tumors and large scale Phase III trials are indicated to definitively establish the impact of thymosIn therapy in lung cancer patients treated with radiotherapy. Expand
A New Immunomodulatory Therapy for Severe Sepsis: Ulinastatin Plus Thymosin α 1
TLDR
Combined immunomodulatory therapy with ulinastatin plus thymosin α1 appears to yield improved survival for patients with sepsis; this finding should be verified in larger clinical trials. Expand
Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects.
TLDR
The combination of DTIC + TA1 + IL-2 is active in the treatment of advanced melanoma, with acceptable toxicity, however, even more active regimens are needed, and the interactions between thymic hormones and cytokines should be further explored. Expand
Thymosin α1 in combination with cytokines and chemotherapy for the treatment of cancer
TLDR
The main data supporting a pivotal role of Tα 1 in such combination protocols are reviewed and special mention of the molecular mechanisms underlying the effects of T α 1 on immune effector cells as well as on target tumour cells are provided. Expand
[Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin].
TLDR
Treatment by the combining anti-inflammatory and immune enhancing agents can significantly improve the outcome of severe sepsis and the efficacy seems to be dose dependent on. Expand
Thymosins: chemistry and biological properties in health and disease
TLDR
The historical background that has generated present interest in the actions of the thymosins in biological therapy is reviewed and the chemical characterisation of the biologically active Thymosin fraction 5 is discussed. Expand
...
1
2
3
4
5
...